Groundbreaking Diabetes Gene Therapy Shows Promise with Non-Viral Delivery System

Researchers at Genprex, Inc. made significant strides in diabetes gene therapy by presenting positive preclinical data on GPX-002, a novel therapy for Type 1 and Type 2 diabetes, at the 85th American Diabetes Association Scientific Session in Chicago. The study demonstrated the effectiveness of a non-viral lipid nanoparticle delivery system, which could allow for repeat dosing and potentially improve treatment outcomes. By transforming alpha cells in the pancreas into functional beta-like cells, GPX-002 shows promise in restoring normal blood glucose levels in diabetes models.

Key Takeaways:

• Genprex's GPX-002 gene therapy uses a novel non-viral lipid nanoparticle delivery system, which has shown promise in preclinical studies.
• The therapy has the potential to allow for repeat dosing, which may be beneficial for patients with diabetes.
• GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin and restore normal blood glucose levels in diabetes models.
• The non-viral delivery system may eliminate the need for immunosuppression, as there is no immune response against lipid nanoparticles.
• Genprex is exploring the use of this delivery system, in addition to its ongoing preclinical studies using an AAV construct.
• The pioneering research on GPX-002 is aimed at developing an alternative delivery system for this transdifferentiation therapy that can be administered more than once.
• Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas.
• GPX-002 has been exclusively licensed from the University of Pittsburgh and is currently being developed for the treatment of both Type 1 and Type 2 diabetes.

Statistics:

• 9 lipid nanoparticles were evaluated for transfection efficiency in isolated mouse Islets of Langerhans.
• 2 LNPs were highly efficient in transfecting α- and β-cells in isolated mouse Islets of Langerhans.
• 100 times more luciferase activity was observed in the pancreas than in other organs after infusion of the LNP with a luciferase mRNA payload into the mouse common bile duct.
• The study used a patented lipid, LipexSil, which was less toxic than a commercially used lipid in vaccines.

Sources:

• Genprex. Genprex, Inc. Press Release (June 23, 2025)
• 85th American Diabetes Association (ADA) Scientific Session in Chicago. Presentation: Title: Selecting Lipid Nanoparticles for Transfection of Islets of Langerhans Cells. Poster Number: 1567-B.